CTOs on the Move

Meda Pharmaceuticals

www.medapharma.us

 
Meda is a leading international specialty pharma company with a broad product portfolio reaching more than 80% of the global pharmaceutical market. Sales at the end of 2014 amounted to more than SEK 15 billion (pro forma SEK 18.7 billion). Meda is thereby the 48th largest pharmaceutical company in the world. At the end of 2014 Meda had 5,202 (3,326) employees, 2,996 (2,009) of which worked in sales and marketing. The company’s main focus is sales and marketing and Meda has its own sales organizations in more than 60 countries. Sales and marketing activities are carried out via distributors in ...
  • Number of Employees: 250-1000
  • Annual Revenue: $250-500 Million
  • www.medapharma.us
  • 265 Davidson Ave Ste 300
    Somerset, NJ USA 08873
  • Phone: 732.564.2200

Executives

Name Title Contact Details

Similar Companies

North Bend Medical Center

NBMC is a multi-specialty, regional medical center with more than 400 employees and 70 medical providers representing approximately 20 specialties

JDS Pharmaceuticals

JDS Pharmaceuticals is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

VistaGen

VistaGen (Nasdaq: VTGN) is a late clinical-stage, CNS-focused biopharmaceutical company striving to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. The Company is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those that are currently available. VistaGen`s clinical-stage candidates are targeting multiple forms of anxiety and depression. They belong to a new class of drugs known as pherines, which are odorless, tasteless, neuroactive steroids that bind to distinct receptors on chemosensory neurons in the nasal passages and can impact the limbic amygdala without systemic uptake or direct activity on CNS neurons in the brain. VistaGen`s lead candidate, PH94B, is a nasally administered spray currently in multiple Phase 3 trials in the U.S., with results anticipated in 2022. Should ongoing Phase 3 studies be successful, PH94B has the potential to be the first FDA-approved, fast-acting, acute treatment of anxiety for adults with social anxiety disorder. With an experienced leadership team, VistaGen is passionate about transforming mental health care and redefining what is possible in the treatment of anxiety and depression.

Fluid Air

Fluid Air, Inc. is a Aurora, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Regernon Pharmaceuticals

Regernon Pharmaceuticals Inc. is a Tarrytown, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.